Kalaris Therapeutics (NASDAQ: KLRS) has announced the appointment of Laurie Keating to its board of directors (BOD), effective August 1, 2026, and the departure of Morana Jovan-Embiricos from the board.
Ms. Keating currently serves as chair of the BOD of PepGen (NASDAQ: PEPG) and as a member of the BOD of Immuneering Corp. (NASDAQ: IMRX).
In a statement, David Hallal, chairman of the BOD, commented, “We’re delighted to welcome Laurie to the Kalaris Board of Directors. She has extensive strategic, operational, and legal expertise spanning multiple therapeutic areas and development stages. Laurie will be an outstanding addition to our Board, and we look forward to her contributions and guidance as we continue to grow Kalaris. I also want to thank Morana for her service to Kalaris over the past year. She was a valuable member of our Board and helped us make significant advances in the development of TH103 and in our evolution as a public biotech company.”
